Lv1
8 积分 2024-10-25 加入
Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors
1天前
已完结
Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update
1天前
求助中
Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques
3天前
已完结
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
6天前
已完结
Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands
7天前
已完结
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
7天前
已完结
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
8天前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Effects of miR-143 overexpression on proliferation, apoptosis, EGFR and downstream signaling pathways in PC9/GR cell line
1个月前
已完结
Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells
2个月前
已完结
皖公网安备34019202002308
